Browsing articles from "April, 2023"

Retina Resources

 //  No Comments

Anti-VEGF Medications for Adults

Retina Consent Forms

Intravitreal Time-out Video and Recommendations

Failure to Diagnose Retinal Detachments Digest

Related Resources: 

Documentation of Ophthalmic Care

Endophthalmitis Malpractice Claims

Endophthalmitis Digest

Responding to Unanticipated Outcomes

Management of Acute Retinal Ischemia

 

 

 

New and Updated Resources

 //  No Comments

April 5, 2023

Dear OMIC Insureds:

We are pleased to announce new and updated risk management resources:

Our updated Anti-VEGF Medications for Adults presents suggestions to increase patient safety and decrease the likelihood of lawsuits related to these drugs. It also provides information about our sample consent documents for anti-VEGF agents, including new sample consent forms for two biosimilar drugs, Byooviz™ and Cimerli™ .
 
We also have a new sample consent form for the steroid injection, Xipere®.

Coming Soon: a new sample consent form for Syforvre™, a treatment for geographic atrophy (GA).

If you have questions, contact us for confidential risk management advice at riskmanagement@omic.com or call us at 1-800-562-6642 and enter 4 for Risk Management.

Sincerely,

Jane Mock, CPHRM, OMIC Risk Manager

 




Six reasons OMIC is the best choice for ophthalmologists in America.

Best at defending claims.

An ophthalmologist pays nearly half a million dollars in premiums over the course of a career. Premium paid is directly related to a carrier’s claims experience. OMIC has a higher win rate taking tough cases to trial, full consent to settle (no hammer) clause, and access to the best experts. OMIC pays 25% less per claim than other carriers. As a result, OMIC has consistently maintained lower base rates than multispecialty carriers in the U.S.

61864684